SureTrader
Home > Boards > US Listed > Biotechs >

Neurotrope Inc. (NTRP)

NTRP RSS Feed
Add NTRP Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, runncoach, Cyosol
Search This Board: 
Last Post: 4/24/2018 11:02:38 AM - Followers: 71 - Board type: Free - Posts Today: 0


 

Description:
Neurotrope, Inc. (also known as Neurotrope BioScience) is an American biopharmaceutical company focused on developing a platform of drugs intended for treating various neurological disorders such as Alzheimer's Disease, Fragile X Syndrome, and Niemann–Pick type C. It is incorporated in Nevada, headquartered in New York City, and is listed on the NASDAQ since 2017.

For more information, visit: http://www.neurotropebioscience.com/

Market Information (as of February 28, 2018 unless otherwise stated):
Symbol: NTRP
Market Value:
$68,558,259
Authorized Shares: 150,000,000
Outstanding Shares:
7,907,527
Public Float: 5,900,000
Warrants:
- Series A Warrants to purchase 49,449 shares of our common stock at an exercise price of $0.32 per share, with an expiration date five years from the date of issuance.
- Series C Warrants to purchase 78,616 shares of our common stock at an exercise price of $0.32 per share, with an expiration date of five years from the date of issuance.
- Series E Warrants, which are contingent upon the exercise of the Series C Warrants, to purchase 819,914 shares of our common stock at an exercise price of $32.00 per share, with an expiration date that is five years from the date of the initial exercise of the Series C Warrants.
- Series F Warrants to purchase 3,751,033 shares of our common stock at an exercise price of $12.80 per share, with an expiration date five years from the date of issuance.
- Placement agent warrants to purchase 21,707 shares of our common stock at an exercise price of $0.32 per share.
- Placement agent warrants to purchase 382,887 shares of our common stock at an exercise price of $6.40 per share.
Options outstanding (as of December 31, 2017): 1,345,835
Shares after dilution (Outstanding shares + Warrants + Options): 14,356,968
Market value after dilution: $124,474,913

For more information, see the latest annual report here: https://www.sec.gov/Archives/edgar/data/1513856/000114420418013105/tv487391_10k.htm#a_009
Company Presentations:
Paradigm Shift in the Treatment of Alzheimer’s: http://neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/HomePage-Forms/Neurotrope%20%20100516.pdf
AD Presentation: http://www.neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/HomePage-Forms/AD%20Presentation.pdf
AAIC 2017: http://www.neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/HomePage-Forms/AAICF.pdf
Sachs Conference: http://www.neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/HomePage-Forms/Sachs%20Conference%20Presentation%20January%202018.pdf
Noble Conference Presentation: http://noble.mediasite.com/mediasite/Play/f9cc934c8a0148f3b6a234de3e4e6f571d?catalog=6f8e7abd-96e3-462f-8035-f48126f80846
Noble Conference Alzheimer's Disease Panel: http://noble.mediasite.com/mediasite/Play/911da4f57eff4257a83b9711230158831d?catalog=6f8e7abd-96e3-462f-8035-f48126f80846
Bio Ceo Conference 2018: https://www.veracast.com/webcasts/bio/ceoinvestor2018/78131219022.cfm?0.0725690394275

Useful links:
Patents by Daniel L. Alkon: https://patents.justia.com/inventor/daniel-l-alkon
Phase 2a and compassionate use patient results: https://content.iospress.com/articles/journal-of-alzheimers-disease/jad170161?resultNumber=0&totalResults=3&start=0&q=neurotrope&resultsPageSize=10&rows=10
Phase 2b results: https://www.prnewswire.com/news-releases/neurotropes-bryostatin-improves-cognition-in-patients-with-advanced-alzheimers-disease-based-on-further-analysis-of-phase-2-clinical-trial-data-300578025.html
Relevant research articles: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138460239
SureTrader
NTRP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
NTRP News: Statement of Changes in Beneficial Ownership (4) 03/16/2018 04:07:39 PM
NTRP News: Statement of Changes in Beneficial Ownership (4) 03/15/2018 05:10:27 PM
NTRP News: Statement of Changes in Beneficial Ownership (4) 03/15/2018 05:10:27 PM
NTRP News: Statement of Changes in Beneficial Ownership (4) 03/15/2018 05:10:02 PM
NTRP News: Statement of Changes in Beneficial Ownership (4) 03/15/2018 05:10:02 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#5681  Sticky Note Here's the corporate presentation: http://noble.mediasite.com/mediasite/Play/f9 Cyosol 02/05/18 01:55:24 PM
#710  Sticky Note Why I will be watching but not investing XenaLives 02/14/17 10:51:33 AM
#6177   True that's why I think we all agree Whoopddew 04/24/18 11:02:38 AM
#6176   Yeah and we'll all be there in some runncoach 04/24/18 10:10:02 AM
#6175   I know some of us are here because Wildginger 04/24/18 09:34:09 AM
#6174   Watched this last night. Really tough runncoach 04/23/18 01:18:51 PM
#6173   The thing that makes AD so serious isn't Cyosol 04/23/18 12:39:07 PM
#6172   If you've never experienced someone with Alzheimer's it's Whoopddew 04/23/18 11:16:30 AM
#6171   "The decision was made at the recommendation of InTheTrenches 04/23/18 11:00:02 AM
#6170   Interesting https://www.cbsnews.com/news/alzheimers-disease-following-a-couple-f FooBarAndGrill 04/23/18 10:49:16 AM
#6169   Another Amyloid down. https://www.marketwatch.com/story/prothena-shares-plummet- grich1 04/23/18 10:23:29 AM
#6168   I don't think I still do. It runncoach 04/19/18 11:05:20 AM
#6167   Do you happen to have a link to Cyosol 04/19/18 10:46:44 AM
#6166   That's pretty much what the Roth report said runncoach 04/19/18 10:40:10 AM
#6165   They certainly have more potent drugs in development, Cyosol 04/19/18 10:38:35 AM
#6164   They will be valuable and some will likely runncoach 04/19/18 10:29:31 AM
#6163   The patents and the other PKCe 30+ activators/drugs grich1 04/19/18 10:25:24 AM
#6162   Trenches a lot folks don't understand the market runncoach 04/19/18 10:21:23 AM
#6161   Something else to note is how the biotech Cyosol 04/19/18 10:19:45 AM
#6160   I agree with the thread. InTheTrenches 04/19/18 10:15:12 AM
#6159   I honestly don't know how the bryology X runncoach 04/19/18 10:08:00 AM
#6158   Great article, even if it's clearly biased and Cyosol 04/19/18 09:53:22 AM
#6157   Your post reminded me of a SA article runncoach 04/19/18 07:44:10 AM
#6156   I just realized that Biogen is in deep Cyosol 04/19/18 04:51:34 AM
#6155   Poor fellow suffers from the same PSEN1 genetic runncoach 04/18/18 09:48:33 PM
#6154   My bet is that if the stock hits Whatsupp 04/18/18 09:33:49 AM
#6153   Rarely is actual interim data released by a InTheTrenches 04/17/18 04:54:41 PM
#6152   Very, very unlikely. Possibly if we had runncoach 04/17/18 04:28:41 PM
#6151   If this thing breaks through $9 again, I Cyosol 04/17/18 04:23:47 PM
#6150   I've seen companies pull the plug on ongoing Whoopddew 04/17/18 04:22:41 PM
#6149   That's great. I can't wait until the runncoach 04/17/18 04:02:09 PM
#6148   Was also told they have additional results to Whatsupp 04/17/18 04:00:06 PM
#6147   Makes sense. Would love to see them runncoach 04/17/18 03:30:44 PM
#6146   My info is that they are shooting for Whatsupp 04/17/18 03:04:55 PM
#6145   Yes it would. Several disappointments and delays from runncoach 04/17/18 12:10:06 PM
#6144   A bit of activity this morning be nice Whoopddew 04/17/18 11:16:15 AM
#6143   If bryostatin becomes FDA approved its the low runncoach 04/16/18 04:08:11 PM
#6142   Something that concerns me (and excites me at Cyosol 04/16/18 04:00:32 PM
#6141   Certainly likely IMO. runncoach 04/16/18 03:34:32 PM
#6140   I'm seeing some trades execute at prices with Cyosol 04/16/18 03:33:12 PM
#6135   Welcome Leo! The data is there for FooBarAndGrill 04/16/18 10:35:17 AM
#6134   So begins the personal research. LakeshoreLeo1953 04/16/18 09:49:23 AM
#6133   Provided that bryostatin gains approval, the most important runncoach 04/14/18 09:11:34 AM
#6132   Some interesting excerpts from the 10K: Cyosol 04/14/18 07:55:45 AM
#6131   Could be. Cyosol 04/13/18 09:01:28 PM
#6130   Six institutional investors added stakes last quarter. LaurieM 04/13/18 07:05:52 PM
#6129   I'm not sure that's true. runncoach 04/13/18 04:19:46 PM
#6128   I think the partnerships with academic institutions are Cyosol 04/13/18 04:18:32 PM
#6127   I hope they do raise some funds at runncoach 04/13/18 04:07:12 PM
#6126   Considering how Neurotrope spent $12 million last year Cyosol 04/13/18 04:02:02 PM
#6125   They've certainly been one of our biggest believers runncoach 04/13/18 02:34:17 PM
#6124   Just because it's so quiet here. https://macondaily.com/2018/04/12/neurotrope-i FooBarAndGrill 04/13/18 02:30:55 PM
PostSubject